Latest News from "The Pink Sheet" DAILY

AstraZeneca Takes Out Antibiotic Firm Novexel, With Cash Back from Forest

AZ will pay up to $505 million and split antibiotic cocktail rights with Novexel partner Forest, which in turn will pay more than $200 million to AZ.   read more

 

Roche Can Launch Mircera 10 Months Before Amgen's EPO Patent Expires

Amgen inked a license agreement with Roche in settling its patent infringement suit.   read more

 

FDA: Vytorin "Unlikely" To Cause Cancer, But More Data Coming

SHARP and IMPROVE-IT trials will allow the agency to "further assess" the potential risk.   read more

 

Novartis Offers $120 Million For Corthera Eyeing Phase III Acute Cardiology Product

Relaxin enables the pharma to expand its reach in acute cardiology as its mega-drug Diovan faces patent expiries.   read more

 

Swine Flu Draws Schools Into Vaccination Network

CDC official says that the pandemic-related effort helps bolster the mass vaccination system, even as public interest in the H1N1 vaccine declines somewhat.   read more

 

Ovos Plots Vivimind Cognitive Supplement Launch, Awaits FDA Reply

Ovos treads a largely ignored legal pathway for ingredients previously studied as investigational new drugs. A nod from FDA for the ingredient homotaurine in Ovos' product would affirm the pathway and pave the way for other ingredients..   read more

"The Pink Sheet" DAILY - Daily, in-depth analysis of the key developments shaping the biopharma industry. Not a subscriber? To register for a free trial, click here